FDA OKs Low-Dose Colchicine for Broad CV Indication

In the LoDoCo-2 trial, the anti-inflammatory drug cut the risk of cardiovascular events by one third when added to standard prevention therapies in patients with chronic coronary disease. And in the COLCOT study, use of colchicine reduced cardiovascular events by 23% compared with placebo in patients with a recent MI.

He pointed out that the indication for Lodoco was very broad, simply stating that it can be used in in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. But Ridker pointed out that, while the label does not specify that Lodoco has to be used in addition to statin therapy, he believes that it will be used as additional therapy to statins in the vast majority of patients.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA OKs Drug for Cholestatic Pruritus in Alagille SyndromeOdevixibat is indicated for treatment of cholestatic pruritus associated with Alagille syndrome in patients as young as 12 months. It marks the second indication for the drug.
Source: Medscape - 🏆 386. / 55 Read more »

Sen. Chuck Schumer calls on Congress & FDA to take action on nationwide drug shortageSen. Chuck Schumer is calling on Congress and the Food and Drug Administration to take action on a nationwide drug shortage.
Source: CBSNewYork - 🏆 268. / 63 Read more »